Californian Chase Pharmaceuticals has made two appointments to its senior leadership team.
Scott Giacobello (pictured right) becomes chief financial officer at the clinical-stage biopharma company, bringing almost 25 years of experience in finance and accounting.
Most recently, Giacobello served as vice president of finance for global research and development at Allergan, and has held financial positions at Black & Decker and Ernst & Young.
Meanwhile, Gary Charbonneau (pictured below) has been appointed as senior vice president for regulatory affairs and operations.
Charbonneau joins Chase with over 25 years of experience in regulatory, quality and research and development operations.
He moves from Allergan, where he spent 14 years in a number of senior regulatory positions, including his most recent role as vice president of international regulatory affairs.
Charbonneau also brings experience from Amgen, Baxter, Novo Nordisk and Roche.
Douglas Ingram, chief executive officer at Chase, said: “I could not be more delighted to welcome Scott and Gary to Chase.
“With its robust intellectual property, pharmaceutical assets and elegant development strategy, Chase has the opportunity to profoundly reshape the approach to the symptomatic treatment of Alzheimer’s disease.
“Scott and Gary have the proven track records, enthusiasm and commitment to operational excellence that will help Chase succeed in improving the lives of millions of patients suffering from this devastating disease.”